SAN ANTONIO -- Preoperative radiotherapy (RT) plus PD-1 inhibitor pembrolizumab (Keytruda) significantly increased immune ...

Sacituzumab govitecan and pembrolizumab showed a manageable safety profile in PD-L1–positive metastatic TNBC, with lower dose reduction or discontinuation rates than chemotherapy. The combination ...

Early MRI predicts pathologic complete response and long-term outcomes in TNBC patients receiving pembrolizumab.

Chronic immune-related adverse events occur in more than a third of patients with early-stage TNBC treated with pembrolizumab.

Licensing partner Zydus brings extensive commercial experience, marketing more than 225 FDA-approved medicines, providing a ...

In this study, researchers investigated long-term outcomes from a real-world cohort of patients with stage IV melanoma treated with pembrolizumab following progression on prior therapies.

Zydus Lifesciences Limited (including its subsidiaries and affiliates), an innovation-led life-sciences company, with an ...

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...

Preoperative radiation improved T-cell infiltration among patients with hormone receptor-positive, HER2-negative breast ...

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has advised Intas ...

During a live event, Moshe C. Ornstein, MD, MA, discussed the recommended regimens for non–clear cell renal cell carcinoma ...